ARCALIS is pleased to announce its participation in the 32nd Annual Meeting of the Japan Society of Gene and Cell Therapy (JSGCT 2026), taking place in Osaka, Japan.
Our Business Development Division member, Dr. Tetsuo Yoshida, will present a poster entitled:

Innovative Technologies Enabling the Development of High-Quality mRNA Therapeutics and Vaccines
 — mRNA Sequence Design, Minimization of dsRNA & pppRNA Impurities, and Organ-Selective Lipid Nanoparticles —

The presentation will showcase ARCALIS’ innovative technologies supporting the development of high-quality mRNA therapeutics and vaccines, including:

• Advanced mRNA sequence design technologies (codon optimization and saRNA platform)
• Minimization of dsRNA and pppRNA impurities
• Organ-selective lipid nanoparticle (LNP) technologies

These integrated technologies address key challenges in mRNA design, manufacturing, and delivery, helping accelerate the development of safer and more effective next-generation RNA medicines.

【Event Details】

Official Website: The 32nd Annual Meeting of Japan Society of Gene and Cell Therapy | Do Convention INC
 Date: July 23-25 (Thu-Sat), 2026
 Venue: Osaka International Convention Center (Grand Cube Osaka), Osaka, Japan

【Poster Presentation】

Title:
 Innovative Technologies Enabling the Development of High-Quality mRNA Therapeutics and Vaccines
 — mRNA Sequence Design, Minimization of dsRNA & pppRNA Impurities, and Organ-Selective Lipid Nanoparticles —
Presenter: Dr. Tetsuo Yoshida　 (Business Development Division, ARCALIS)
Poster Number: P2-39
Venue: Room 5 (Exhibition Hall)
Session Date: Saturday, July 25, 2026
Session Time: 1:30-2:20 PM
Presentation Time: 1:30-1:55 PM

We warmly invite all attendees to visit our poster and connect with our team to discuss the future of mRNA therapeutics and vaccines.

We look forward to meaningful discussions and connections with you in Osaka.